Developing Oral Recombinant Products to address Gastrointestinal Diseases and Microbiome Related Conditions;
Report Available here: http://www.lifescicapital.com/equity-research/AzurRx/
NEW YORK, NY / ACCESSWIRE / March 1, 2017 /LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of AzurRx BioPharma (NasdaqCM: AZRX), a biopharmaceutical company focused on the development of oral recombinant products to address gastrointestinal diseases and microbiome related conditions. The Company's lead candidate, MS1819, is a recombinant yeast lipase that is being developed for the treatment of exocrine pancreatic insufficiency (EPI).
AzurRx has reported positive data from a Phase Ib study that tested the safety, tolerability, and efficacy of MS1819. The randomized, double-blind, placebo controlled trial enrolled 12 patients with EPI due to CP or pancreatectomy. The trial met its primary endpoint of improvement in steatorrhea. Key secondary endpoints that were also met. Regarding safety, there were no serious adverse events (AEs) and no unexpected serious adverse reactions. MS1819 is currently in a Phase IIa study in patients with EPI caused by CP. Topline results from the trial are expected in the first half of 2017. A Phase IIb crossover trial is expected to begin in the first half of 2017.
AzurRx is also developing AZ1101, an oral, non-absorbable, synthetic ß-lactamase. This unique candidate is being developed for the prevention of hospital-acquired infections and antibiotic-induced diarrhea in patients being treated with beta-lactam antibiotics. The program is currently in preclinical stages, and the Company intends to launch clinical trials in 2017.
In a 47 page Initiation Report, LifeSci Capital explains the preclinical and clinical data supporting MS1819 as a treatment for EPI. We also outline the market opportunity and discuss the landscape of approved agents and those in development.
Dr. Isaacson's full Initiation Report, including important disclosures, is available to download, at no cost, at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on AzurRx BioPharma as developments occur.
The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.
About LifeSci Capital:
LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.
Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
SOURCE: LifeSci Capital, LLC
This article appears in: